New Therapies for Ovarian Cancer Patients with BRAF Gene Mutation

Targeting mutation on the BRAF gene may be an effective therapy for ovarian cancer patients with a tumor mutation in the BRAF gene. This research highlights the importance of using targeted therapies for rare ovarian tumor types.

Ovarian cancer with mutations in the BRAF gene may respond well to treatments that target the gene, research at the Westmead Institute for Medical Research reports.

BRAF inhibitors block the activity of mutated BRAF gene. They are currently used to treat patients with melanoma, which often have mutations in the BRAF gene.

Ovarian Cancer | Cancer in the Ovaries - Causes, Symptoms, Treatment & Prevention
Ovarian cancer affects both the ovaries and is referred to as the 'silent killer' as the symptoms go unnoticed until the disease advances.

TOP INSIGHT

Targeted therapies that target mutation on the BRAF gene may be an effective therapy for ovarian cancer patients with a tumor mutation in the gene.

The study showed that BRAF inhibitors may be effective at treating a rare type of ovarian cancer, called low-grade serous cancer, which more commonly affects younger women.

PhD student Dr Tania Moujaber from the Westmead Institute for Medical Research examined information from more than 1,000 ovarian cancer patients across Australia, including from the Australian Ovarian Cancer Study, to identify cases of low-grade serous cancer.

Dr Moujaber identified nine women with the BRAF mutation. Four of these patients relapsed soon after regular primary treatment.

Ovarian Cysts - Types, Causes, Symptoms, Diagnosis, Treatment
Ovarian cysts are fluid-filled sacs in the ovary. Mostly detected on pelvic examination. Cyst removal is needed if the cysts cause pain, cancerous or symptomatic.

"Two of these women went into a clinical trial to test BRAF inhibitors, following our research which identified their BRAF mutations," Dr Moujaber explained.

"Both have had excellent, long-lasting responses.

Polycystic Ovarian Syndrome - Overview
Polycystic ovarian syndrome is the most common hormonal disorder among women of reproductive age and can cause infertility.

"In contrast, the other two women received standard treatment several years before our analysis, and sadly rapidly deteriorated and died."

Dr Moujaber said the findings are encouraging for women with BRAF-mutated ovarian cancers, who may not respond to conventional chemotherapy.

About Cancer in Women
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.

"This treatment may not be effective for all cancers with a BRAF mutation, but we are optimistic that a positive response is likely in patients with ovarian cancer," she said.

The research was conducted by the ovarian cancer research team at the Westmead Institute for Medical Research (WIMR), led by Professor Anna deFazio and Professor Paul Harnett, together with collaborators in Melbourne and Brisbane.

Outcomes for women with ovarian cancer are slowly improving, but the 5-year survival rate is still only 40 percent.

Professor deFazio said that one barrier to improving outcomes is that ovarian cancer is currently treated as a single disease.

"Chemotherapy and surgery are the standard treatment for women with ovarian cancer, but each patient responds differently," Professor deFazio said.

"Ovarian cancer is a complex and diverse disease, so we can't assume the same treatment will work for everyone.

"This research highlights the importance of using targeted therapies for rare ovarian tumor types, such as those with BRAF mutations," Professor deFazio concluded.

Professor deFazio and her team are leading a longitudinal study, called INOVATe, which aims to integrate this level of precision medicine into routine care for all women with ovarian cancer.

Source-Eurekalert